Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Literal federal measure citations: H.R. 4299
2026 · 1st Quarter (Jan 1 - Mar 31)
TAKEDA PHARMACEUTICALS AMERICA, INC.
Filed by TIBER CREEK GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 18, 2026
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- TIBER CREEK GROUP
- Filing UUID
- 29c57150-9172-4f29-9a7a-1b4d4df6aa2e
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to Plasma-Derived Therapies; Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to National Priority Voucher (CNPV) program.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.